Compare · NVO vs PRTA
NVO vs PRTA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 445.5x PRTA ($483.6M).
- Over the past year, NVO is down 12.1% and PRTA is up 12.8% - PRTA leads by 24.9 points.
- PRTA has been more active in the news (10 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 22 for PRTA).
- Company
- Novo Nordisk A/S
- Prothena Corporation plc
- Price
- -
- -
- Market cap
- $215.46B
- $483.6M
- 1M return
- -2.08%
- +8.27%
- 1Y return
- -12.07%
- +12.80%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 10
- Recent ratings
- 25
- 22
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PRTA
- Large owner Scully William P bought $439,430 worth of Ordinary Shares (50,000 units at $8.79), increasing direct ownership by 7% to 800,000 units (SEC Form 4)
- SEC Form 3 filed by new insider Fennell Todd W.
- Large owner Scully William P received a gift of 336,000 units of Ordinary Shares and gifted 627,553 units of Ordinary Shares, decreasing direct ownership by 28% to 750,000 units (SEC Form 4)
- Large owner Scully William P received a gift of 251,553 units of Ordinary Shares, increasing direct ownership by 32% to 1,041,553 units (SEC Form 4)
- SEC Form 3 filed by new insider Fennell Todd W.
- Large owner Scully William P bought $323,220 worth of Ordinary Shares (37,500 units at $8.62), increasing direct ownership by 4% to 790,000 units (SEC Form 4)
- SEC Form 10-Q filed by Prothena Corporation plc
- Prothena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
- Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc